NCT06730529RecruitingNot Applicable
The Value of 68Ga-FAPI PET/CT in Preoperative Evaluation of Thyroid Cancer with Lymph Node Metastases
Conditions
Trial Snapshot
- Phase
- Not Applicable
- Status
- Recruiting
- Sponsor
- Ruijin Hospital
- Enrollment
- 40
- Locations
- 1
- Primary Endpoint
- Clinical staging of thyroid cancer with lymph node metastasis
Study Overview
Brief Summary
This study aims to investigate the value of 68Ga-FAPI in the preoperative evaluation of thyroid cancer of different pathologic types.
Detailed Description
The investigators will number all participants, create a medical record file, and record their basic information (gender, age) as well as contact information and medical history information. All participants will undergo a 68Ga-FAPI PET/CT before surgery. The imaging response measurements will be compared with the histopathological results as gold standard.
Study Design
- Study Type
- Observational
- Observational Model
- Other
- Time Perspective
- Prospective
Eligibility Criteria
- Ages
- 16 Years to 80 Years (Child, Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Pathological and clinical diagnosis of thyroid cancer with lymph node metastases.
- •Signed and dated informed consent form.
- •Commitment to comply with research procedures and co-operation in the implementation of the full research process.
- •Aged 16-80 years old.
Exclusion Criteria
- •Patients with serious illnesses that researchers consider unsuitable for participation in this clinical study. Such as severe heart and lung failure, severe bone marrow suppression, severe liver and kidney dysfunction, etc.
- •Intestinal perforation, complete intestinal obstruction.
- •Pregnant women and women who may be pregnant, women who are breastfeeding.
- •Non-compliant person.
Outcomes
Primary Outcomes
Clinical staging of thyroid cancer with lymph node metastasis
Time Frame: Within 1 week after enrollment
The value of 68Ga-FAPI PET/CT in the evaluation of thyroid cancer with lymph node metastases in clinical staging
Secondary Outcomes
- Standardized uptake value(SUV)(Within 1 week after enrollment)
- Disease free survival(3 years)
Investigators
Hu Jiajia
Deputy director
Ruijin Hospital
Study Sites (1)
Loading locations...
Similar Trials
Recruiting
Not Applicable
The Value of 68Ga-FAPI PET/CT in the Efficacy Evaluation of Advanced Unresectable Hepatocellular Carcinoma Patients Undergoing Systemic Antitumor TherapyHepatocellular Carcinoma (HCC)NCT06746194Ruijin Hospital40
Unknown
Not Applicable
Preoperative Abdominal Enhanced CT, 18F-FDG PET/CT and 68Ga-FAPI PET/CT in Peritoneal Carcinomatosis of Gastric CancerEnhanced CT18F-FDG PET/CT68Ga-FAPI PET/CTPeritoneal CarcinomatosisGastric CancerNCT04778345Fujian Medical University72
Recruiting
Early Phase 1
68Ga-FAPI-FS PET/CT and PET/MR in Pancreatic CancerPancreatic CancerNCT05875753Peking Union Medical College Hospital50
Active, not recruiting
Not Applicable
FAPI PET for Response Evaluation and Prognosis Prediction in Liver and Biliary Cancer Patients Treated With PD-1 Combination TherapyBile Duct CancerHepatocellular CarcinomaNCT05662488Peking Union Medical College Hospital25
Recruiting
Not Applicable
68Ga-TCR-FAPI PET/CT Guided Precision Surgery for MTCMedullary Thyroid CancerPrositron Emission TomographyFibroblast Activation Protein InhibitorSurgeryNCT06277180Cancer Institute and Hospital, Chinese Academy of Medical Sciences50